264 related articles for article (PubMed ID: 24615289)
1. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety.
Kuwayama Y; Nomura A
Adv Ther; 2014 Apr; 31(4):461-71. PubMed ID: 24615289
[TBL] [Abstract][Full Text] [Related]
2. Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence.
Kuwayama Y; Hashimoto M; Kakegawa R; Nomura A; Shimada F
Adv Ther; 2017 Jun; 34(6):1411-1425. PubMed ID: 28502035
[TBL] [Abstract][Full Text] [Related]
3. Fixed Combination of Travoprost and Timolol Maleate Reduces Intraocular Pressure in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Prospective Multicenter Open-Label Study.
Nakano T; Mizoue S; Fuse N; Iwase A; Matsumoto S; Yoshikawa K
Adv Ther; 2015 Sep; 32(9):823-37. PubMed ID: 26424331
[TBL] [Abstract][Full Text] [Related]
4. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
Ge J; Li X; Sun X; He X; Zhang H
Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
[TBL] [Abstract][Full Text] [Related]
5. Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment.
Oddone F; Kirwan J; Lopez-Lopez F; Zimina M; Fassari C; Holló G;
Adv Ther; 2022 Aug; 39(8):3501-3521. PubMed ID: 35524840
[TBL] [Abstract][Full Text] [Related]
6. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
[TBL] [Abstract][Full Text] [Related]
7. A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components.
Pfeiffer N; Traverso CE; Lorenz K; Saarela V; Liinamaa J; Uusitalo H; Astakhov Y; Boiko E; Ropo A;
Adv Ther; 2014 Dec; 31(12):1228-46. PubMed ID: 25447269
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study.
Tanihara H; Kakuda T; Sano T; Kanno T; Imada R; Shingaki W; Gunji R
Adv Ther; 2019 Feb; 36(2):333-343. PubMed ID: 30610614
[TBL] [Abstract][Full Text] [Related]
9. Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride.
Wong TT; Aung T; Ho CL
Clin Exp Ophthalmol; 2018 Dec; 46(9):1028-1034. PubMed ID: 29802759
[TBL] [Abstract][Full Text] [Related]
10. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension.
Erb C; Lanzl I; Seidova SF; Kimmich F
Adv Ther; 2011 Jul; 28(7):575-85. PubMed ID: 21725844
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Ocular Pulse Amplitude-Lowering Effects of Tafluprost and Latanoprost by Dynamic Contour Tonometry.
Park SH; Yoo SH; Ha SJ
J Ocul Pharmacol Ther; 2015 Dec; 31(10):617-22. PubMed ID: 26348718
[TBL] [Abstract][Full Text] [Related]
12. Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan.
Nakazawa T; Takahashi K; Kuwayama Y; Nomura A; Shimada F
Adv Ther; 2022 Mar; 39(3):1359-1374. PubMed ID: 35072890
[TBL] [Abstract][Full Text] [Related]
13. Prospective Observational Post-marketing Study of Tafluprost 0.0015%/Timolol 0.5% Combination Ophthalmic Solution for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety.
Takagi Y; Osaki H; Yamashita T; Kai Y
Ophthalmol Ther; 2016 Dec; 5(2):191-206. PubMed ID: 27492380
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Ocular Pulse Amplitude Lowering Effects of Preservative-Free Tafluprost and Preservative-Free Dorzolamide-Timolol Fixed Combination Eyedrops.
Seo du R; Ha SJ
Biomed Res Int; 2015; 2015():435874. PubMed ID: 26557671
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study.
Oddone F; Tanga L; Kóthy P; Holló G;
Adv Ther; 2020 Apr; 37(4):1436-1451. PubMed ID: 32072493
[TBL] [Abstract][Full Text] [Related]
16. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension.
Konstas AG; Quaranta L; Katsanos A; Riva I; Tsai JC; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Floriani I; Haidich AB
Br J Ophthalmol; 2013 Dec; 97(12):1510-5. PubMed ID: 23681371
[TBL] [Abstract][Full Text] [Related]
17. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China.
Sun X; Liu Q; Tang X; Yao K; Li Y; Yang J; Zhang M; Yuan H; Zheng Y; Li W; Peng H
BMC Ophthalmol; 2022 Aug; 22(1):332. PubMed ID: 35932001
[TBL] [Abstract][Full Text] [Related]
19. Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions.
Kumagami T; Wakiyama H; Kusano M; Kajiyama A; Miura Y; Uematsu M; Yoneda A; Kurihara J; Suzuma K; Kitaoka T
J Ocul Pharmacol Ther; 2014 May; 30(4):340-5. PubMed ID: 24576066
[TBL] [Abstract][Full Text] [Related]
20. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
Lopes JF; Hubatsch DA; Amaris P
BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]